Since 1997, Battelle's Medical Research and Evaluation Facility has supported the U.S. Army Medical Research Institute of Chemical Defense program in evaluating candidate drugs for topical pretreatment and therapeutic protection against sulfur mustard (SM) injury using the mouse ear vesicant model (MEVM). Several compounds have proven to reduce tissue damage when tested as pre- and/or post-treatments against SM. In order to gain some additional information on the toxicity potential of four of these compounds, a study was conducted applying various doses of each compound to both ears and observing the mice for 14 days. Clinical observations and body weights over time were recorded. A simple motor incapacitation test was also administered. The motor incapacitation test consisted of placing a mouse on the top of a 5"x 5" screen that was subsequently inverted. Mice climbing back to the top of the 5"x 5" screen grid within 1 minute of inversion passed the performance test. Mice which fell or remained on the bottom of the grid for the one minute test period fail. The four compounds tested were 4-Methyl-2-mercaptopyridine-1-oxide (ICD# 1308), indomethacin (ICD# 2086), BAL (ICD# 2525), and 8-Methyl-N-vanillyl-6-nonenamide or capsaicin (ICD# 3537). Lethality was observed only at the high doses of ICD #2086. A dose response in average body weight changes from Day 0 to 14 was observed for the other three compounds. Body weight gains were significantly more variable at the high doses of these compounds. Motor incapacitation testing demonstrated no evidence of gross behavioral deficit for any of the compounds tested.